Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company developing small molecule medicines to modulate altered proteins, will hold a virtual R&D update on February 18, 2025. The webcast, originating from Halle (Saale) / Munich, Germany on February 11, 2025, will feature management and Key Opinion Leaders (KOLs) discussing varoglutamstat. Presentations will cover varoglutamstat’s impact on kidney function, its clinical development plan for kidney disease, its market potential, and allow for a Q&A session.
KOL speakers include:
- Tobias B. Huber, MD, Chair of the Center of Internal Medicine and Director of the III. Department of Medicine at the University Medical Center Hamburg-Eppendorf (UKE), Germany, acting as Medical Advisor.
- Kevin Carroll, PhD, CEO of KJC Statistics, providing statistical expertise.
Webcast details
Date: February 18, 2025
Time: 3:00 pm CET / 9:00 am EST
Event details and registration are available at:
###
About Varoglutamstat
Varoglutamstat (PQ912) is a potent, selective inhibitor of human glutaminyl cyclases QPCT and QPCTL, showing potential in inflammatory and fibrotic diseases, neurodegenerative diseases, and cancer. Initially developed for Alzheimer’s disease (AD), it’s been studied in several clinical trials. The Phase 2b VIVIAD study in early AD assessed its effects on kidney function (eGFR) and kidney inflammation/fibrosis biomarkers. eGFR was also a safety parameter in the U.S. VIVA-MIND Phase 2 study.
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company developing innovative small molecule medicines. The company uses its expertise in post-translational modifications to create medicines modulating disease-altered proteins. Its pipeline includes oral small molecule inhibitors for Alzheimer’s disease, inflammatory and fibrotic disorders (including kidney disease), and cancer.
Vivoryon Forward-Looking Statements
This release contains forward-looking statements regarding Vivoryon Therapeutics N.V.’s business strategy, management plans, future operations, market estimates, product availability forecasts, etc. Words like “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “should,” and “will,” and similar expressions, identify these statements. These statements are not guarantees and are based on current expectations and assumptions. Numerous known and unknown risks and uncertainties could materially affect results. Actual results may differ materially from those expressed or implied in these forward-looking statements. Therefore, undue reliance should not be placed on them. Risk factors are discussed in the company’s published annual financial statements. This release speaks only as of its date. The Company does not undertake to update any information or forward-looking statements herein, except as legally required.
For more information, please contact:
Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:
LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email:
Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email:
Attachment
“`